featured
FDA Approves Voranigo for Grade 2 Astrocytoma or Oligodendroglioma
This is the first FDA-approved systemic therapy for patients with a susceptible IDH1 or IDH2 mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.